Table 4 Comparison of the efficacy of immune checkpoint inhibitors in SCLC
From: Current and future therapies for small cell lung carcinoma
Drug | Company | Target | Status | Approval Year | Trial | Strategy | Efficacy |
|---|---|---|---|---|---|---|---|
Atezolizumab | Roche | IgG1 targeting PD-L1 | FDA approved | 2019/3/1 | IMpower133 | Combined with chemotherapy for first-line |
|
Durvalumab | AstraZeneca UK Ltd | IgG1 targeting PD-L1 | FDA approved | 2020/3/1 | CASPIAN | Combined with chemotherapy for first-line |
|
Adebelimab | Hengrui Pharmaceutical | IgG1 targeting PD-L1 | NMPA approved | 2023/3/1 | CAPSTONE-1 | Combined with chemotherapy for first-line |
|
Serplulimab | Shanghai Henlius Biotech, Inc | IgG4 targeting PD-1 | NMPA approved | 2022/1/1 | ASTRUM-005 | Combined with chemotherapy for first-line |
|
Tislelizumab | Beigene | IgG4 targeting PD-1 | NMPA approved | – | RATIONALE 312 | Combined with chemotherapy for first-line |
|
Nivolumab | Bristol-Myers Squibb Company | IgG4 targeting PD-1 | FDA approved | 2018/8/1 | CheckMate032 | Combined with ipilimumab for second/multi lines |
|
Withdrawn | 2020/12/1 | CheckMate 451 | Combined with ipilimumab for first-line |
| |||
CheckMate 331 | Monotherapy for second/multi-lines |
| |||||
Pembrolizumab | MSD | IgG4 targeting PD-1 | FDA approved | 2019/6/1 | KEYNOTE-028 and KEYNOTE-158 | Monotherapy for second/multi-lines |
|
Withdrawn | 2020/1/1 | KEYNOTE-604 | Combined with chemotherapy for first-line |
|
